JP2012526558A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012526558A5 JP2012526558A5 JP2012511010A JP2012511010A JP2012526558A5 JP 2012526558 A5 JP2012526558 A5 JP 2012526558A5 JP 2012511010 A JP2012511010 A JP 2012511010A JP 2012511010 A JP2012511010 A JP 2012511010A JP 2012526558 A5 JP2012526558 A5 JP 2012526558A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- nos
- antigen
- binding portion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims description 86
- 102000036639 antigens Human genes 0.000 claims description 86
- 108091007433 antigens Proteins 0.000 claims description 86
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 42
- 102000013135 CD52 Antigen Human genes 0.000 claims description 35
- 108010065524 CD52 Antigen Proteins 0.000 claims description 35
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 30
- 206010028980 Neoplasm Diseases 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 18
- 150000007523 nucleic acids Chemical class 0.000 claims description 18
- 201000011510 cancer Diseases 0.000 claims description 17
- 101000980814 Homo sapiens CAMPATH-1 antigen Proteins 0.000 claims description 15
- 102000043738 human CD52 Human genes 0.000 claims description 15
- 108020004707 nucleic acids Proteins 0.000 claims description 12
- 102000039446 nucleic acids Human genes 0.000 claims description 12
- 239000002773 nucleotide Substances 0.000 claims description 12
- 125000003729 nucleotide group Chemical group 0.000 claims description 12
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 10
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 9
- 210000004027 cell Anatomy 0.000 claims description 9
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 8
- 208000023275 Autoimmune disease Diseases 0.000 claims description 7
- 206010029113 Neovascularisation Diseases 0.000 claims description 4
- 230000033115 angiogenesis Effects 0.000 claims description 4
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims description 4
- 230000004540 complement-dependent cytotoxicity Effects 0.000 claims description 4
- 210000004602 germ cell Anatomy 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 3
- 229940122760 T cell stimulant Drugs 0.000 claims description 3
- 210000000822 natural killer cell Anatomy 0.000 claims description 3
- 210000000440 neutrophil Anatomy 0.000 claims description 3
- 210000003289 regulatory T cell Anatomy 0.000 claims description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 2
- 102100021943 C-C motif chemokine 2 Human genes 0.000 claims description 2
- 101710155857 C-C motif chemokine 2 Proteins 0.000 claims description 2
- 108090001005 Interleukin-6 Proteins 0.000 claims description 2
- 102000004889 Interleukin-6 Human genes 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 2
- 208000004732 Systemic Vasculitis Diseases 0.000 claims description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 2
- 206010047115 Vasculitis Diseases 0.000 claims description 2
- 235000004279 alanine Nutrition 0.000 claims description 2
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims description 2
- 229960000548 alemtuzumab Drugs 0.000 claims description 2
- 230000000779 depleting effect Effects 0.000 claims description 2
- 239000000539 dimer Substances 0.000 claims description 2
- 230000004068 intracellular signaling Effects 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 230000036210 malignancy Effects 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 230000003472 neutralizing effect Effects 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 2
- 238000002054 transplantation Methods 0.000 claims description 2
- 206010062016 Immunosuppression Diseases 0.000 claims 1
- 230000001506 immunosuppresive effect Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000008685 targeting Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 6
- 229940079593 drug Drugs 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17783709P | 2009-05-13 | 2009-05-13 | |
| US61/177,837 | 2009-05-13 | ||
| PCT/US2010/034704 WO2010132659A2 (en) | 2009-05-13 | 2010-05-13 | Anti-human cd52 immunoglobulins |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014145770A Division JP2014195474A (ja) | 2009-05-13 | 2014-07-16 | 抗ヒトｃｄ５２免疫グロブリン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012526558A JP2012526558A (ja) | 2012-11-01 |
| JP2012526558A5 true JP2012526558A5 (https=) | 2014-09-04 |
| JP5894912B2 JP5894912B2 (ja) | 2016-03-30 |
Family
ID=43085579
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012511010A Active JP5894912B2 (ja) | 2009-05-13 | 2010-05-13 | 抗ヒトｃｄ５２免疫グロブリン |
| JP2014145770A Withdrawn JP2014195474A (ja) | 2009-05-13 | 2014-07-16 | 抗ヒトｃｄ５２免疫グロブリン |
| JP2016023418A Withdrawn JP2016093194A (ja) | 2009-05-13 | 2016-02-10 | 抗ヒトｃｄ５２免疫グロブリン |
| JP2017231850A Withdrawn JP2018029624A (ja) | 2009-05-13 | 2017-12-01 | 抗ヒトｃｄ５２免疫グロブリン |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014145770A Withdrawn JP2014195474A (ja) | 2009-05-13 | 2014-07-16 | 抗ヒトｃｄ５２免疫グロブリン |
| JP2016023418A Withdrawn JP2016093194A (ja) | 2009-05-13 | 2016-02-10 | 抗ヒトｃｄ５２免疫グロブリン |
| JP2017231850A Withdrawn JP2018029624A (ja) | 2009-05-13 | 2017-12-01 | 抗ヒトｃｄ５２免疫グロブリン |
Country Status (19)
| Country | Link |
|---|---|
| US (5) | US8617554B2 (https=) |
| EP (3) | EP2998405B1 (https=) |
| JP (4) | JP5894912B2 (https=) |
| KR (5) | KR101537840B1 (https=) |
| CN (3) | CN104231084B (https=) |
| AR (1) | AR076770A1 (https=) |
| AU (1) | AU2010249003B2 (https=) |
| BR (1) | BRPI1013085A2 (https=) |
| CA (2) | CA2761800C (https=) |
| HK (2) | HK1222682A1 (https=) |
| IL (2) | IL216141B (https=) |
| MX (1) | MX2011012047A (https=) |
| MY (1) | MY160126A (https=) |
| NZ (2) | NZ596384A (https=) |
| RU (2) | RU2016142225A (https=) |
| SG (2) | SG176060A1 (https=) |
| TW (3) | TW201825115A (https=) |
| WO (1) | WO2010132659A2 (https=) |
| ZA (1) | ZA201108077B (https=) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2722184A1 (en) | 2008-04-25 | 2009-10-29 | Duke University | Regulatory b cells and their uses |
| EP2998405B1 (en) | 2009-05-13 | 2019-12-11 | Genzyme Corporation | Anti-human cd52 immunoglobulins |
| CA2761885A1 (en) | 2009-05-13 | 2010-11-18 | Genzyme Corporation | Methods and compositions for treating lupus |
| US9814740B2 (en) * | 2010-12-21 | 2017-11-14 | Duke University | Methods and compositions combining immunotherapy with monocyte activation |
| JP6104794B2 (ja) | 2011-04-18 | 2017-03-29 | 国立大学法人 東京大学 | 抗ｉｔｍ２ａ抗体を用いる癌の診断および治療 |
| GB201109238D0 (en) * | 2011-06-01 | 2011-07-13 | Antitope Ltd | Antibodies |
| SG10201603411WA (en) | 2011-10-28 | 2016-07-28 | Teva Pharmaceuticals Australia Pty Ltd | Polypeptide constructs and uses thereof |
| WO2013185165A1 (en) * | 2012-06-14 | 2013-12-19 | The Walter And Eliza Hall Institute Of Medical Research | Cd-52 antibodies and their use in determining and enhancing an immune response in a subject |
| US10017739B2 (en) | 2012-09-06 | 2018-07-10 | Duke University | Methods of expanding and assessing B cells and using expanded B cells to treat disease |
| WO2014066271A1 (en) * | 2012-10-22 | 2014-05-01 | Becton, Dickinson And Company | Non-b-lineage cells capable of producing antibody |
| US9816989B2 (en) | 2013-03-12 | 2017-11-14 | Institute of Arthritis Research, LLC | Immunologically active polypeptide |
| CA2902026C (en) | 2013-03-13 | 2023-08-29 | Prothena Biosciences Limited | Tau immunotherapy |
| AR095199A1 (es) * | 2013-03-15 | 2015-09-30 | Genzyme Corp | Anticuerpos anti-cd52 |
| KR102042174B1 (ko) | 2013-03-29 | 2019-11-08 | 삼성전자주식회사 | 인간화 및 친화도 성숙된 항 ｃ-Ｍｅｔ 항체 및 그의 용도 |
| KR102060540B1 (ko) * | 2013-04-03 | 2019-12-31 | 삼성전자주식회사 | 항 c-Met 항체 및 항 Ang2 항체를 포함하는 병용 투여용 약학 조성물 |
| EP2983790A2 (en) | 2013-04-09 | 2016-02-17 | Boston Biomedical, Inc. | Methods for treating cancer |
| KR102186363B1 (ko) * | 2013-09-06 | 2020-12-04 | 삼성전자주식회사 | c-Met 저해제 및 베타-카테닌 저해제를 포함하는 병용 투여용 약학 조성물 |
| KR102192591B1 (ko) * | 2013-09-09 | 2020-12-18 | 삼성전자주식회사 | c-Met 저해제 및 c-Myc 저해제를 포함하는 병용 투여용 약학 조성물 |
| MX2017015618A (es) | 2015-06-03 | 2018-08-15 | Boston Biomedical Inc | Composiciones que comprenden un inhibidor de la autorrenovación y diferenciación de células madre cancerosas y un agente inmunoterapéutico para su uso en el tratamiento del cáncer. |
| PE20190208A1 (es) | 2016-05-02 | 2019-02-07 | Prothena Biosciences Ltd | Anticuerpos que reconocen tau |
| EP3452507B1 (en) | 2016-05-02 | 2022-10-19 | Prothena Biosciences Limited | Tau immunotherapy |
| CA3022515A1 (en) | 2016-05-02 | 2017-11-09 | Prothena Biosciences Limited | Antibodies recognizing tau |
| JP7106563B2 (ja) | 2016-11-29 | 2022-07-26 | スミトモ ファーマ オンコロジー， インコーポレイテッド | ナフトフラン誘導体、その調製、および使用方法 |
| WO2018112407A1 (en) | 2016-12-15 | 2018-06-21 | Duke University | Antibodies and methods for depleting regulatory b10 cells and use in combination with immune checkpoint inhibitors |
| US20200299399A1 (en) * | 2017-04-21 | 2020-09-24 | Genzyme Corporation | Treatment of Multiple Sclerosis with Anti-CD52 Antibodies |
| CN110881274B (zh) | 2017-05-02 | 2024-11-15 | 普罗塞纳生物科学有限公司 | 识别tau的抗体 |
| CA3062656A1 (en) | 2017-05-17 | 2018-11-22 | Boston Biomedical, Inc. | Methods for treating cancer |
| GB201710836D0 (en) * | 2017-07-05 | 2017-08-16 | Ucl Business Plc | ROR1 Car T-Cells |
| KR20200103751A (ko) | 2017-12-20 | 2020-09-02 | 라디뮨 테라퓨틱스 인코포레이티드 | 센트린-1에 대한 항체, 이의 제조 방법, 및 용도 |
| MX2021006756A (es) * | 2018-12-19 | 2021-09-28 | Humabs Biomed Sa | Anticuerpos que neutralizan el virus de la hepatitis b y usos de los mismos. |
| MY206794A (en) | 2018-12-20 | 2025-01-08 | Humabs Biomed Sa | Combination hbv therapy |
| EP3935083A4 (en) | 2019-03-03 | 2022-11-30 | Prothena Biosciences Limited | Antibodies recognizing tau |
| CN109929835A (zh) * | 2019-03-27 | 2019-06-25 | 中国人民解放军第四军医大学 | 一种鼠单克隆抗体功能轻链可变区基因的扩增方法 |
| PE20220568A1 (es) | 2019-05-21 | 2022-04-20 | Novartis Ag | Moleculas de union a cd19 y usos de las mismas |
| AU2020299024A1 (en) * | 2019-07-02 | 2022-01-20 | Telix Pharmaceuticals (Innovations) Pty Ltd | Antibodies against CAIX with reduced affinity for the neonatal Fc receptor |
| US12560598B2 (en) | 2020-03-11 | 2026-02-24 | Genesis Intelligence, Llc | Cartridge-based automated rapid test analyzer |
| CN115515984B (zh) * | 2020-05-08 | 2026-02-06 | 亘利生物科技(上海)有限公司 | 一种抗cd19抗体的抗体及其制备和应用 |
| WO2022109172A1 (en) * | 2020-11-19 | 2022-05-27 | Genzyme Corporation | Flow cytometry attenuated reporter expression (flare) multiple reporter system and methods of use thereof |
| AR124414A1 (es) | 2020-12-18 | 2023-03-22 | Century Therapeutics Inc | Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable |
| WO2025031965A1 (en) * | 2023-08-04 | 2025-02-13 | Cimeio Therapeutics Ag | Discernible cell surface protein variants of cd52 for use in cell therapy |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6054561A (en) | 1984-02-08 | 2000-04-25 | Chiron Corporation | Antigen-binding sites of antibody molecules specific for cancer antigens |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US4970198A (en) | 1985-10-17 | 1990-11-13 | American Cyanamid Company | Antitumor antibiotics (LL-E33288 complex) |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| WO1987006265A1 (fr) | 1986-04-17 | 1987-10-22 | Kyowa Hakko Kogyo Co., Ltd. | Nouveaux composes dc-88a et dc-89a1, et procede pour leur preparation |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
| ATE243754T1 (de) | 1987-05-21 | 2003-07-15 | Micromet Ag | Multifunktionelle proteine mit vorbestimmter zielsetzung |
| JP3095168B2 (ja) | 1988-02-05 | 2000-10-03 | エル． モリソン，シェリー | ドメイン‐変性不変部を有する抗体 |
| WO1989007452A1 (en) | 1988-02-12 | 1989-08-24 | Medical Research Council | Improvements in or relating to antibodies |
| JP2598116B2 (ja) | 1988-12-28 | 1997-04-09 | 協和醗酵工業株式会社 | 新規物質ｄｃ１１３ |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| JP2510335B2 (ja) | 1989-07-03 | 1996-06-26 | 協和醗酵工業株式会社 | Ｄｃ―８８ａ誘導体 |
| US5187186A (en) | 1989-07-03 | 1993-02-16 | Kyowa Hakko Kogyo Co., Ltd. | Pyrroloindole derivatives |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| ATE300615T1 (de) | 1990-08-29 | 2005-08-15 | Genpharm Int | Transgene mäuse fähig zur produktion heterologer antikörper |
| GB9022543D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Antibody production |
| GB9022547D0 (en) | 1990-10-17 | 1990-11-28 | Wellcome Found | Purified immunoglobulin |
| GB9108056D0 (en) * | 1991-04-16 | 1991-06-05 | Hale Geoffrey | Synthetic antigen |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US5264586A (en) | 1991-07-17 | 1993-11-23 | The Scripps Research Institute | Analogs of calicheamicin gamma1I, method of making and using the same |
| US5269388A (en) | 1991-11-12 | 1993-12-14 | Stress-Tek, Inc. | Weighing bed |
| GB9125768D0 (en) * | 1991-12-04 | 1992-02-05 | Hale Geoffrey | Therapeutic method |
| ES2149768T3 (es) | 1992-03-25 | 2000-11-16 | Immunogen Inc | Conjugados de agentes enlazantes de celulas derivados de cc-1065. |
| WO1994026087A2 (en) | 1993-05-14 | 1994-11-24 | Connor Kim C O | Recombinant protein production and insect cell culture and process |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| US7119248B1 (en) | 1994-04-12 | 2006-10-10 | Miltenyi Biotec Gmbh | Antibodies against epitopes with homology to self antigens, methods of preparation and applications thereof |
| CA2165819C (en) | 1994-04-22 | 2005-12-27 | Nobuyoshi Amishiro | Dc-89 derivatives |
| US5550246A (en) | 1994-09-07 | 1996-08-27 | The Scripps Research Institute | Calicheamicin mimics |
| US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
| US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
| GB9603507D0 (en) | 1996-02-20 | 1996-04-17 | Isis Innovation | Antibody variants |
| US7147851B1 (en) | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
| WO1998052976A1 (en) | 1997-05-21 | 1998-11-26 | Biovation Limited | Method for the production of non-immunogenic proteins |
| WO2000034317A2 (en) | 1998-12-08 | 2000-06-15 | Biovation Limited | Method for reducing immunogenicity of proteins |
| ES2276708T3 (es) | 1999-11-24 | 2007-07-01 | Immunogen, Inc. | Agentes citotoxicos que comprenden taxanos y su uso terapeutico. |
| BRPI0108923B8 (pt) | 2000-03-03 | 2021-05-25 | Cambridge Antibody Tech Limited | elemento de ligação específico, ácido nucleico isolado, célula hospedeira, métodos para produzir um elemento de ligação específico ou domínio vh ou vl de anticorpo, e, para obter um elemento de ligação específico que liga eotaxina |
| US6333410B1 (en) | 2000-08-18 | 2001-12-25 | Immunogen, Inc. | Process for the preparation and purification of thiol-containing maytansinoids |
| US7465790B2 (en) | 2000-10-09 | 2008-12-16 | Isis Innovation, Inc. | Therapeutic antibodies |
| US20020132983A1 (en) | 2000-11-30 | 2002-09-19 | Junghans Richard P. | Antibodies as chimeric effector cell receptors against tumor antigens |
| CA2467633C (en) | 2001-12-03 | 2012-03-27 | Abgenix, Inc. | Antibody categorization based on binding characteristics |
| AU2003217912A1 (en) * | 2002-03-01 | 2003-09-16 | Xencor | Antibody optimization |
| WO2004042032A2 (en) | 2002-11-01 | 2004-05-21 | The Ohio State University Research Foundation | Cytogenetic abnormalities that are predictive of response to therapy for chronic lymphocytic leukemia |
| CN1225480C (zh) * | 2002-12-18 | 2005-11-02 | 马菁 | 抗cd52单克隆抗体、其编码序列及应用 |
| US7534427B2 (en) | 2002-12-31 | 2009-05-19 | Immunomedics, Inc. | Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins |
| AU2004226492A1 (en) * | 2003-03-31 | 2004-10-14 | Kirin Beer Kabushiki Kaisha | Method of inducing differentiation and proliferating regulatory T cell by anti-CD52 antibody and medicinal composition therefor |
| WO2005017149A1 (en) | 2003-06-03 | 2005-02-24 | Cell Genesys, Inc. | Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site |
| WO2005042581A2 (en) | 2003-11-01 | 2005-05-12 | Biovation Ltd. | Modified anti-cd52 antibody |
| US20060204496A1 (en) * | 2003-11-28 | 2006-09-14 | Tetsuo Kojima | Agonist antibody against heteroreceptor |
| ITRM20030601A1 (it) | 2003-12-24 | 2005-06-25 | Lay Line Genomics Spa | Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti. |
| US7655229B2 (en) | 2004-09-02 | 2010-02-02 | Chan Andrew C | Anti-FC-gamma RIIB receptor antibody and uses therefor |
| WO2006028956A2 (en) * | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Anti-fc-gamma riib receptor antibody and uses therefor |
| WO2006086469A2 (en) | 2005-02-08 | 2006-08-17 | Genzyme Corporation | Antibodies to tgfbeta |
| JP2009504136A (ja) * | 2005-05-24 | 2009-02-05 | アベスタゲン リミテッド | 慢性リンパ性白血病治療のためのｃｄ５２に対するモノクローナル抗体産生のための組み換え法 |
| DK1888113T3 (da) | 2005-05-27 | 2014-09-01 | Biogen Idec Inc | Tweak-bindende antistoffer |
| WO2007076927A1 (en) * | 2005-12-30 | 2007-07-12 | Merck Patent Gmbh | Anti-il-6 antibodies preventing the binding of il-6 complexed with il-6ralpha to gp130 |
| WO2007121233A1 (en) * | 2006-04-12 | 2007-10-25 | Genzyme Corporation | Methods of treating autoimmune diseases |
| KR101583587B1 (ko) | 2006-09-13 | 2016-01-08 | 젠자임 코포레이션 | 캠패스-1ｈ에 의한 다발성 경화증 (ｍｓ)의 치료 |
| JP5337055B2 (ja) | 2007-02-28 | 2013-11-06 | メルク・シャープ・アンド・ドーム・コーポレーション | 免疫性障害の処置のための組合せ治療 |
| US20100178293A1 (en) * | 2007-06-22 | 2010-07-15 | Olaf Weber | Use of antibodies against the cd52 antigen for the treatment of neurological disorders, particularly transmissible spongiform encephalopathy and alzheimer's disease |
| EP2998405B1 (en) | 2009-05-13 | 2019-12-11 | Genzyme Corporation | Anti-human cd52 immunoglobulins |
| WO2010132697A2 (en) | 2009-05-13 | 2010-11-18 | Genzyme Corporation | Methods and compositions for treatment |
| CA2761885A1 (en) | 2009-05-13 | 2010-11-18 | Genzyme Corporation | Methods and compositions for treating lupus |
| SI2454284T1 (en) | 2009-07-15 | 2018-07-31 | Aimm Therapeutics B.V. | Compounds that specifically bind to Gram-positive bacteria |
| DK2593594T3 (en) | 2010-07-16 | 2017-12-11 | Adimab Llc | ANTIBODY LIBRARIES |
| ITMI20110376A1 (it) | 2011-03-10 | 2012-09-11 | Wilic Sarl | Aerogeneratore raffreddato a fluido |
| GB201109238D0 (en) | 2011-06-01 | 2011-07-13 | Antitope Ltd | Antibodies |
| AR095199A1 (es) | 2013-03-15 | 2015-09-30 | Genzyme Corp | Anticuerpos anti-cd52 |
| PT3204425T (pt) | 2014-10-09 | 2020-12-18 | Genzyme Corp | Conjugados anticorpo fármaco glicomanipulados |
| US20200299399A1 (en) | 2017-04-21 | 2020-09-24 | Genzyme Corporation | Treatment of Multiple Sclerosis with Anti-CD52 Antibodies |
-
2010
- 2010-05-13 EP EP15191351.4A patent/EP2998405B1/en active Active
- 2010-05-13 AR ARP100101677A patent/AR076770A1/es not_active Application Discontinuation
- 2010-05-13 AU AU2010249003A patent/AU2010249003B2/en not_active Ceased
- 2010-05-13 MX MX2011012047A patent/MX2011012047A/es active IP Right Grant
- 2010-05-13 JP JP2012511010A patent/JP5894912B2/ja active Active
- 2010-05-13 TW TW106123171A patent/TW201825115A/zh unknown
- 2010-05-13 NZ NZ596384A patent/NZ596384A/en not_active IP Right Cessation
- 2010-05-13 CN CN201410379748.7A patent/CN104231084B/zh active Active
- 2010-05-13 SG SG2011083847A patent/SG176060A1/en unknown
- 2010-05-13 KR KR1020117029662A patent/KR101537840B1/ko not_active Expired - Fee Related
- 2010-05-13 US US13/320,019 patent/US8617554B2/en active Active
- 2010-05-13 MY MYPI2011005455A patent/MY160126A/en unknown
- 2010-05-13 TW TW104144762A patent/TWI614267B/zh not_active IP Right Cessation
- 2010-05-13 KR KR1020157036932A patent/KR20160005143A/ko not_active Withdrawn
- 2010-05-13 WO PCT/US2010/034704 patent/WO2010132659A2/en not_active Ceased
- 2010-05-13 KR KR1020147020065A patent/KR20140102764A/ko not_active Withdrawn
- 2010-05-13 TW TW099115371A patent/TWI529247B/zh not_active IP Right Cessation
- 2010-05-13 KR KR1020177026871A patent/KR20170113704A/ko not_active Ceased
- 2010-05-13 CN CN201910228216.6A patent/CN110016081A/zh active Pending
- 2010-05-13 CA CA2761800A patent/CA2761800C/en active Active
- 2010-05-13 CA CA2939492A patent/CA2939492C/en active Active
- 2010-05-13 BR BRPI1013085-3A patent/BRPI1013085A2/pt not_active IP Right Cessation
- 2010-05-13 KR KR1020167022759A patent/KR20160103160A/ko not_active Ceased
- 2010-05-13 CN CN2010800312662A patent/CN102459628A/zh active Pending
- 2010-05-13 SG SG10201608169QA patent/SG10201608169QA/en unknown
- 2010-05-13 RU RU2016142225A patent/RU2016142225A/ru not_active Application Discontinuation
- 2010-05-13 RU RU2011150516/10A patent/RU2603743C2/ru not_active IP Right Cessation
- 2010-05-13 NZ NZ621170A patent/NZ621170A/en not_active IP Right Cessation
- 2010-05-13 EP EP10775530A patent/EP2429582A4/en not_active Withdrawn
- 2010-05-13 EP EP19214547.2A patent/EP3683317A3/en not_active Withdrawn
-
2011
- 2011-11-03 IL IL216141A patent/IL216141B/en not_active IP Right Cessation
- 2011-11-03 ZA ZA2011/08077A patent/ZA201108077B/en unknown
-
2012
- 2012-09-10 HK HK16110806.5A patent/HK1222682A1/en unknown
-
2013
- 2013-11-26 US US14/091,083 patent/US20140341910A1/en not_active Abandoned
-
2014
- 2014-07-16 JP JP2014145770A patent/JP2014195474A/ja not_active Withdrawn
-
2015
- 2015-06-18 HK HK15105820.8A patent/HK1205152A1/xx unknown
- 2015-09-24 US US14/864,736 patent/US20160208010A1/en not_active Abandoned
-
2016
- 2016-02-10 JP JP2016023418A patent/JP2016093194A/ja not_active Withdrawn
-
2017
- 2017-12-01 JP JP2017231850A patent/JP2018029624A/ja not_active Withdrawn
-
2018
- 2018-10-28 IL IL262639A patent/IL262639A/en unknown
-
2019
- 2019-04-10 US US16/380,389 patent/US20200040091A1/en not_active Abandoned
-
2021
- 2021-03-03 US US17/191,440 patent/US11945874B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012526558A5 (https=) | ||
| JP7254699B2 (ja) | 抗ｂｃｍａ重鎖のみ抗体 | |
| RU2016142225A (ru) | Иммуноглобулины к cd52 человека | |
| EP3476399B1 (en) | Lag-3 antibody, antigen-binding fragment thereof, and pharmaceutical application thereof | |
| TWI854953B (zh) | 抗ｃｄ３抗體及含有該抗體的分子、及其製造方法 | |
| CN113454119B (zh) | 抗btla抗体 | |
| JP2020531043A (ja) | 抗４−１ｂｂ抗体とその作製及び使用方法 | |
| CN116239698A (zh) | 双功能融合蛋白及其医药用途 | |
| JP2016513467A5 (https=) | ||
| CA3064298A1 (en) | Anti-cd40 antibody, antigen binding fragment thereof and medical use thereof | |
| JP2017537082A5 (https=) | ||
| CA3207791A1 (en) | Anti-cd112r antibody and use thereof | |
| CN111886023A (zh) | 针对tim-3的抗体及其用途 | |
| JP2013519690A5 (https=) | ||
| TW202529810A (zh) | 用於治療噬血球性淋巴組織細胞增生症之ｓｉｒｐ抗體 | |
| TW202523701A (zh) | 用於治療癌症之ｓｉｒｐ抗體 | |
| KR20260026013A (ko) | 항-ccr8 항체, 접합체 및 이의 용도 | |
| JPWO2021068841A5 (https=) | ||
| WO2022228545A1 (en) | Antibodies and variants thereof against human 4-1bb | |
| US20230042316A1 (en) | Monoclonal antibodies that target human cd47 protein | |
| US20240084012A1 (en) | Anti-pd-1/cd47 bispecific antibody and use thereof | |
| WO2024218650A1 (en) | Lilrb1 and lilrb2 antibodies and methods of use thereof | |
| WO2023228082A1 (en) | Anti-tnfr2 antibodies and methods of use thereof | |
| HK40121520A (zh) | 抗-tnfr2抗体及其使用方法 | |
| TW202608477A (zh) | 用於治療愛潑斯坦—巴爾病毒感染之ＳＩＲＰα、β、γ抗體 |